This is a routine divestment by a pre-IPO venture investor. The sale is small relative to market cap and does not imply any change in business fundamentals. Monitor for any Form 4 filings to confirm execution, but no immediate trading action is warranted.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 29 $21.26entry
- T+1 · 5mo ago +4.47%α +3.69% · $22.21
- T+5 · 4mo ago +7.43%α +6.04% · $22.84
- T+20 · 4mo ago +14.96%α +15.24% · $24.44
- T+60 · 8w ago −19.38%α −23.75% · $17.14
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Atlas Venture Opportunity Fund I, L.P., a major early investor, filed a Form 144 notice of intent to sell 64,411 shares of Dyne Therapeutics common stock, valued at approximately $1.33M at the filing date. This represents a routine insider sale by a pre-IPO venture backer and does not signal a change in company outlook.
Key Facts
- Atlas Venture Opportunity Fund I, L.P. filed Form 144 to sell 64,411 shares of Dyne Therapeutics common stock.
- The estimated market value of the proposed sale is approximately $1.33 million.
- The shares were acquired in a private placement on August 7, 2020.
- The insider has sold no other securities in the past 3 months.
Financial Impact
Sale of 64,411 shares valued at approximately $1.33 million, representing a small fraction of the company's $3.6B market cap.
Risk Factors
- None directly from this filing; a large block trade if executed could cause minor short-term price pressure.
- Insider selling by large holders, if sustained, may signal reduced long-term conviction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001628280-26-045818 |
| Document: 0001628280-26-045818-index.html | 0001628280-26-045818 |
| Document: 0001628280-26-045818.txt | 0001628280-26-045818 |
Track record
54 reports on DYN
12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers